What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the app.

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

Ever wondered if DexCom is now a bargain or still priced for perfection? Let's get under the hood to see if the recent headlines match up with what the numbers are really saying. The stock has seen ...

DexCom DXCM shares soared 6.5% in the last trading session to close at $106.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

Dexcom (DXCM) is down 6% in Monday afternoon trading after its anticipated 2023 non-GAAP gross profit margin came in below consensus expectations. The glucose ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 194 % ...

DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...